PRESS RELEASE published on 10/15/2024 at 08:00, 2 years ago HOPIUM renforce sa visibilité à l'international en participant au salon Hydrogen Technology Expo Europe Hopium renforce sa visibilité à l'international en participant au salon Hydrogen Technology Expo Europe pour présenter sa technologie de pile à combustible. Objectif : décarboner les transports lourds Technologie Décarbonation HOPIUM Transports Lourds Hydrogen Technology Expo Europe
PRESS RELEASE published on 10/15/2024 at 08:00, 2 years ago Inside Information / Other news releases OPM presents safety & efficacy data on OPM-101, a novel RIPK2 kinase inhibitor, in healthy volunteers at UEG Week 2024 conference, targeting IBD treatment Precision Medicine UEG Week 2024 OPM-101 RIPK2 Kinase Inhibitor IBD Treatment
PRESS RELEASE published on 10/15/2024 at 07:33, 2 years ago ONWARD® Medical signe un accord avec le CEA pour obtenir les droits exclusifs de la technologie d’interface cerveau machine (BCI) WIMAGINE® de Clinatec ONWARD Medical signe un accord avec le CEA pour obtenir les droits exclusifs de la technologie d'interface cerveau machine WIMAGINE de Clinatec, visant à restaurer les mouvements guidés par la pensée après une paralysie Technologie CEA ONWARD Medical Interface Cerveau Machine WIMAGINE
PRESS RELEASE published on 10/15/2024 at 07:30, 2 years ago Atos appoints Philippe Salle Chairman of the Board of Directors with effect from October 14, 2024 and Chairman and Chief Executive Officer from February 01, 2025 Atos appoints Philippe Salle as Chairman of the Board of Directors with immediate effect and Chairman and CEO from February 01, 2025. The appointment follows a rigorous selection process. Salle brings extensive CEO experience to support the business plan and Group restructuring Restructuring Chairman CEO Atos Philippe Salle
PRESS RELEASE published on 10/15/2024 at 07:30, 2 years ago Informations privilégiées / Autres communiqués MaaT Pharma annonce la fin du recrutement de son essai de Phase 3 ARES pour MaaT013 dans le traitement de la maladie aiguë du greffon contre l'hôte. Premiers résultats attendus en janvier 2025 MaaT Pharma MaaT013 Phase 3 ARES Maladie Aiguë Greffon Contre L'hôte
PRESS RELEASE published on 10/15/2024 at 07:30, 2 years ago Inside Information / Other news releases MaaT Pharma completes recruitment of its ARES Phase 3 Trial for MaaT013, a treatment for Acute Graft-versus-Host Disease, with topline results expected in January 2025 Clinical Trial MaaT Pharma MaaT013 ARES Phase 3 Trial Acute Graft-versus-Host Disease
PRESS RELEASE published on 10/15/2024 at 07:30, 2 years ago Atos nomme Philippe Salle Président du Conseil d’administration à compter du 14 octobre 2024 et Président-Directeur général à compter du 1er février 2025 Atos appoints Philippe Salle Chairman of the Board of Directors with effect from October 14, 2024 and Chairman and Chief Executive Officer from February 01, 2025. Philippe Salle brings extensive CEO experience to support the Group's business plan and restructuring Chairman CEO Financial Restructuring Atos Philippe Salle
REGULATED PRESS RELEASE published on 10/15/2024 at 07:01, 2 years ago bioMérieux receives CE-marking for VIDAS® VITAMIN B12 TOTAL, a blood test to measure total Vitamin B12 concentration bioMerieux announces CE-marking for VIDAS Vitamin B12 Total, an automated blood test to measure total B12 concentration in serum or plasma, aiding in the assessment of B12 status and optimizing patient care BioMérieux CE-marking VIDAS Vitamin B12 Total Blood Test
REGULATED PRESS RELEASE published on 10/15/2024 at 07:01, 2 years ago bioMérieux obtient le marquage CE du test sanguin VIDAS® VITAMIN B12 TOTAL mesurant la concentration totale de vitamine B12 bioMérieux obtient le marquage CE pour le test sanguin VIDAS VITAMIN B12 TOTAL mesurant la concentration totale de vitamine B12, renforçant leur gamme d'immunoessais BioMérieux Marquage CE VIDAS Vitamine B12 Test Sanguin
PRESS RELEASE published on 10/15/2024 at 07:00, 2 years ago Growth and market share gains – Cicor thrives in a challenging environment Cicor Technologies Ltd reports 26.3% growth in quarterly sales, focuses on market share gains. The company anticipates sales growth to reach CHF 470-510 million by the end of 2024 Sales Growth Cicor Technologies Ltd Market Share Gains Quarterly Sales CHF 470-510 Million
Published on 11/11/2026 at 03:30, 6 hours 56 minutes ago CoTec Holdings Corp. Files Third Quarter Financial Statements and MD&A and Provides Market Commentary
Published on 11/11/2026 at 00:40, 9 hours 46 minutes ago Upgraded Tunkillia MRE Validates Optimised Scoping Study
Published on 11/10/2026 at 23:30, 10 hours 56 minutes ago CCL Industries Announces 2026 Third Quarter Results
Published on 11/10/2026 at 23:00, 11 hours 26 minutes ago Vanta Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/10/2026 at 23:00, 11 hours 26 minutes ago Battery X Metals Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/11/2026 at 10:10, 16 minutes ago EQS-Adhoc: Hapag-Lloyd further raises its earnings outlook for the current financial year
Published on 11/11/2026 at 10:00, 26 minutes ago GBC AG and Apaton Finance invite investors to the Zefiro Investor Day on November 19, 2026
Published on 11/11/2026 at 09:40, 45 minutes ago Disclosure according to Article 5(1)(b) of the EU Regulation No. 596/2014 and Article 2(3) of the Delegated EU Regulation No. 2016/1052 - 1st Interim Report
Published on 11/11/2026 at 09:25, 1 hour 1 minute ago DOBOT Unveils Three New Products at Its 2026 Robotics Ecosystem Conference
Published on 11/11/2026 at 09:05, 1 hour 21 minutes ago DeepL unveils Aure, its most lifelike Voice AI translation model yet
Published on 11/10/2026 at 18:00, 16 hours 26 minutes ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 16 hours 41 minutes ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 16 hours 51 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 16 hours 54 minutes ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.